Abstract: This disclosure relates to pyrazoline dihydroquinolone derivates, pharmaceutical compositions, and uses. In certain embodiments, the compounds are selective NMDA receptor inhibitors and are useful in therapeutic methods related thereto. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a compound of the following formula: Formula (I) or salts, esters, or prodrugs thereof, as provided herein.
Type:
Application
Filed:
June 27, 2014
Publication date:
December 22, 2016
Applicant:
Emory University
Inventors:
Timothy M. Acker, Dennis C. Liotta, Stephen F. Traynelis
Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Type:
Application
Filed:
August 30, 2016
Publication date:
December 15, 2016
Applicants:
Emory University, Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital, President and Fellows of Harvard College
Inventors:
Gordon Freeman, Arlene Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry
Abstract: The present invention is directed to compounds of Formula IC: wherein the substituents are described herein. These compounds and their pharmaceutically acceptable salts thereof are prostaglandin receptor EP2 antagonists.
Type:
Grant
Filed:
June 19, 2012
Date of Patent:
December 13, 2016
Assignee:
Emory University
Inventors:
Jianxiong Jiang, Thota Ganesh, Yuhong Du, Pahk Thepchatri, Yi Quan, Ray J. Dingledine
Abstract: This disclosure relates to viral particles and nucleic acids encoding an HCV envelope glycoprotein 2 containing a mutation. Viral particles can be created and administered to a subject to illicit an immune response.
Abstract: The systems and devices and methods relate to surgical and percutaneous repair of heart valve regions. The systems and devices are structured to conform to the desired shape of a specific patient. The devices may include a mounting structure and a valve support onto which leaflets of the valve may coapt or rest. The devices may be structured to be mounted directly onto a leaflet of the valve.
Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
Type:
Grant
Filed:
August 18, 2011
Date of Patent:
December 6, 2016
Assignees:
Emory University, The United States of America as represented by the Department of Veterans Affairs
Abstract: Compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering a 7,8-dihydroxyflavone derivative with modified flavone or heterocyclic ring to a subject in need thereof. Methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided.
Abstract: This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: Formula I, or salt, prodrug, or ester thereof wherein X, Y, and R1 and R10 to R13 are described herein.
Type:
Grant
Filed:
October 24, 2012
Date of Patent:
November 22, 2016
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Inventors:
Richard K. Plemper, James P. Snyder, Aiming Sun
Abstract: This disclosure is in the area of research and therapeutics. In certain embodiments, it provides methods to assist in the purification of cell mixtures, e.g., cardiomyocytes, using molecular beacons targeting cell-type specific RNA, e.g. mRNA.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
November 15, 2016
Assignees:
Emory University, Georgia Tech Research Corporation
Inventors:
Young Sup Yoon, Gang Bao, Kiwon Ban, Brian Wile
Abstract: Methods, systems and computer-readable storage media relate to image-guided treatment planning and treatment assessment. The methods, systems, and the computer-readable storage medias according to embodiments can analyze treatment response and can determine an accurate, outcome-based response assessment of treatment (e.g., radiation treatment). The methods may include a method for determining a treatment response. The method may include registering at least a first image data and a second image data of a subject, the first image data corresponding to a first time point, the second image data corresponding to a second time point, the first time point and the second time point being different with respect to a treatment session and/or treatment stage. The method may include processing the registered image to determine a treatment response. The registering may be based on deformable registration.
Abstract: Antibodies or antibody fragments, wherein the antibody or the fragment binds HA domain of influenza virus (e.g. H1N1, H5N1, or both). Also described are cloned human antibodies that bind influenza.
Type:
Grant
Filed:
January 10, 2012
Date of Patent:
October 18, 2016
Assignees:
Emory University, The University of Chicago
Inventors:
Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
Abstract: Antibodies that bind with high affinity to swine H1N1 virus are described. In vivo experiments showed that one such antibody is able to fully protect mice challenged with a lethal dose of swine H1N1 virus. The antibody is also able to cure mice in a therapeutic setting when treated as late as up to 60 hours (2.5 days) after infection with swine H1N1 virus. Also described are recombinant forms of this antibody.
Type:
Grant
Filed:
October 12, 2010
Date of Patent:
October 4, 2016
Assignees:
Emory University, The University of Chicago
Inventors:
Jens Wrammert, Rafi Ahmed, Patrick Wilson
Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Type:
Grant
Filed:
December 30, 2013
Date of Patent:
October 4, 2016
Assignees:
Emory University, Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
Inventors:
Gordon Freeman, Arlene Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry
Abstract: This disclosure relates to manipulating microRNA for the management of neurological disorders and compositions related thereto. In certain embodiments, the disclosure contemplates inhibition of miR324 or miR324-5p, e.g., the use of nucleobase polymers for antisense disruptions or RNA interference of miR-324 expression or for miR324-5p binding in order to increase Kv4.2 expression. In certain embodiments, the disclosure relates to methods of treating or preventing a neurological disease or condition comprising administering an effective amount of an inhibitor to a subject in need thereto.
Type:
Grant
Filed:
September 2, 2014
Date of Patent:
October 4, 2016
Assignee:
Emory University
Inventors:
Gary J. Bassell, Xiaodi Yao, Christina Gross
Abstract: This disclosure relates to the use of drugs to prevent graft versus host disease (GVHD) in a subject after, before, or during a hematopoietic stem cell transplant. In certain embodiments, the drugs are antagonist of vasoactive intestinal peptide signaling. In certain embodiments, the subject has a blood or bone marrow cancer or condition.
Type:
Grant
Filed:
December 5, 2014
Date of Patent:
October 4, 2016
Assignee:
Emory University
Inventors:
Edmund K. Waller, Cynthia R. Giver, Sravanti Rangaraju
Abstract: This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes.
Type:
Grant
Filed:
November 8, 2012
Date of Patent:
October 4, 2016
Assignee:
Emory University
Inventors:
Young-Sup Yoon, Xiaodong Cheng, Ji Woong Han, Antonello Mai
Abstract: The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
Type:
Grant
Filed:
August 29, 2005
Date of Patent:
September 27, 2016
Assignees:
Emory University, The Government of the United States of America, as represented by the Secretary Department of Health and Human Services, National Institutes of Health
Inventors:
Bernard Moss, Linda Wyatt, Harriet L. Robinson
Abstract: The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations, including deletions, at the S68 codon of HIV-RT are provided.
Abstract: The disclosure relates to piperazine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidase.
Type:
Grant
Filed:
June 12, 2012
Date of Patent:
August 30, 2016
Assignee:
Emory University
Inventors:
Thota Ganesh, Aiming Sun, Susane M. Smith, John David Lambeth
Abstract: This disclosure relates to synthetic coupling methods using a catalytic molecule comprising two bonded atoms wherein one atom is an amide nitrogen and the second atom is not nitrogen or carbon, such as sulfur, such as a sufur amide nitrogen bond, typically in a heterocycle, such as substituted benzoisothiazolones and derivatives thereof, as a catalyst in the transformation of hydroxy group containing compounds to amides, esters, ketones, and other carbon to heteroatom or carbon to carbon transformations.
Type:
Application
Filed:
October 8, 2014
Publication date:
August 25, 2016
Applicant:
Emory University
Inventors:
Lanny S. Liebeskind, Matthew Lindale, Pavan Kumar Reddy Gangireddy